These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 17392551)

  • 1. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
    Brooks B; Delaney-Robinson C; Molyneaux L; Yue DK
    J Diabetes Complications; 2008; 22(2):88-95. PubMed ID: 18280438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
    Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    ; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.
    Boyd A; Casselini C; Vinik E; Vinik A
    J Diabetes Sci Technol; 2011 May; 5(3):714-22. PubMed ID: 21722587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.
    Bastyr EJ; Price KL; Bril V;
    Clin Ther; 2005 Aug; 27(8):1278-94. PubMed ID: 16199253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials.
    Tesfaye S; Tandan R; Bastyr EJ; Kles KA; Skljarevski V; Price KL;
    Diabetes Care; 2007 Oct; 30(10):2626-32. PubMed ID: 17623822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
    Valensi P; Le Devehat C; Richard JL; Farez C; Khodabandehlou T; Rosenbloom RA; LeFante C
    J Diabetes Complications; 2005; 19(5):247-53. PubMed ID: 16112498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
    Ekberg K; Brismar T; Johansson BL; Lindström P; Juntti-Berggren L; Norrby A; Berne C; Arnqvist HJ; Bolinder J; Wahren J
    Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Protein kinase C beta-Inhibitor ruboxistaurin].
    Musch A
    Med Monatsschr Pharm; 2005 Aug; 28(8):292-3. PubMed ID: 16128544
    [No Abstract]   [Full Text] [Related]  

  • 15. Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy.
    Vinik AI; Bril V; Litchy WJ; Price KL; Bastyr EJ;
    Muscle Nerve; 2005 Nov; 32(5):619-25. PubMed ID: 16116628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
    Gilbert RE; Kim SA; Tuttle KR; Bakris GL; Toto RD; McGill JB; Haney DJ; Kelly DJ; Anderson PW
    Diabetes Care; 2007 Apr; 30(4):995-6. PubMed ID: 17229944
    [No Abstract]   [Full Text] [Related]  

  • 17. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
    Thisted RA; Klaff L; Schwartz SL; Wymer JP; Culligan NW; Gerard G; Pope LE; Berg JE
    Clin Ther; 2006 Oct; 28(10):1607-18. PubMed ID: 17157116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF gene transfer for diabetic neuropathy.
    Isner JM; Ropper A; Hirst K
    Hum Gene Ther; 2001 Aug; 12(12):1593-4. PubMed ID: 11529248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism.
    Cameron NE; Cotter MA
    Diabetes Metab Res Rev; 2002; 18(4):315-23. PubMed ID: 12203947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.